|
Showing 1 - 1 of
1 matches in All Departments
" . . . the motto for the therapeutics of the future will have to
be de sedibus et causis pharmacorum. " P. EHRLICH, 1909 Exciting
events in the basic disciplines of virology, immunology, and
pharmacology continue to advance the understanding of the
pathogenesis and control of virus diseases. At the same time, the
rational development of antiviral agents is attracting, to an
increasing extent, the interest of workers in other disciplines.
Improvements in technology facilitate the definition of potential
target sites for antiviral intervention and unmask new viral and
host genes. The outcome is a further steady development of new
antiviral agents which approach the "magic bullets" first proposed
by PAUL EHRLICH. Remarkable advances in protein synthetic methods
that yield polypeptides which inhibit active sites of viral
proteins have aided substantially in the basic and clinical study
of these antiviral agents. In addition, the extremely rapid
progression in recombinant DNA techniques, leading to the synthesis
of large quantities of gene products, is also increasing our
opportunities at a dashing pace. New information and developing
technology facilitate research on the mechanism of action,
toxicity, pharmacokinetics, and pharmacodynamics of new agents. The
list of clinically effective antiviral agents is expanding and the
number of potentially useful compounds is growing rapidly. This
book is a combined theoretical text and practical manual which, it
is hoped, will be of use to all who have an interest in virus
diseases, particularly scientists, physicians and graduate
students.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R205
R168
Discovery Miles 1 680
Dope
Blake Anderson, Julian Brand, …
DVD
R59
R23
Discovery Miles 230
Loot
Nadine Gordimer
Paperback
(2)
R205
R168
Discovery Miles 1 680
Loot
Nadine Gordimer
Paperback
(2)
R205
R168
Discovery Miles 1 680
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.